Patients who undergo immunotherapy based on clinical judgment or their own request
Conditions
Interventions
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Study participants voluntarily participate in this trial and sign the informed consent form; 2.Aged >= 18 years and <= 80 years (based on the date of signing the informed consent form), with no restriction on gender; 3.Patients newly diagnosed with malignant tumors and patients scheduled to receive immunotherapy after radiotherapy and chemotherapy; 4.Physical fitness status score: 0~1 point; 5.The expected survival time is more than 12 months; 6.Female study participants of childbearing age, male study participants, and the partners of male study participants agree to use reliable contraceptive methods (such as abstinence, sterilization surgery, contraceptive pills, injectable contraceptive medroxyprogesterone, or subcutaneous implant contraception, etc.) within 6 months after the end of the last study drug infusion; 7.Willing and able to comply with scheduled visits, diagnostic plans, clinical laboratory tests, and other trial procedures.
Exclusion criteria
Exclusion criteria: 1.Previous use of radionuclides with an interval of less than 10 physical half-lives from the time of drug administration in this study; 2.Currently undergoing or planning to participate in any drug or device clinical trial during the study period; 3.Unable to lie flat or remain still during a PET scan, or intolerant of PET scans; 4.Those with a history of fracture or anemia in the past year; 5.Participants had abnormalities in physical examinations, ECG, and clinical laboratory tests during the screening period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum standardized uptake value; | — |
Countries
China
Contacts
Public ContactDong Mengjie
Peking University Shenzhen Hospital
Outcome results
None listed